CA-PSMF
7.7.2021 14:27:13 CEST | Business Wire | Press release
The COVID-19 pandemic took the world by storm in 2020 and drew attention to healthcare performance, access and resource use. Unfortunately, it took the impact of something as monumental as a worldwide pandemic to serve as a reality check about our broken healthcare system, which was built without a foundation for safety, reliability and person-centeredness across the continuum. As we aim to shift into a post-pandemic world, the Patient Safety Movement Foundation (PSMF) , a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, has released the results from its “2021 Patient Safety Awareness Poll.” The survey examined the publics’ perception of patient safety and preventable medical harm and found that the public feels less in control over what happens to their health and that there is still a long way to go to educate the public about medical errors.
Some key findings included:
- Only 53.2% of individuals know what the term “medical error” means and 37% were able to correctly define it.
- It is apparent that there is still much work to do to bring awareness to this worldwide issue, as 87.3% of the respondents had heard little or nothing about medical error or patient harm in their local area.
- Fifty-eight percent of the public is worried about medical errors during “every visit” or “occasionally” – especially outside of high-income countries.
- Only 45.9% of the public feels in control over what happens to their health, down 31% from 2020.
- When asked what key areas of concern were, 50.9% were worried about out-of-pocket costs, 44% were most worried about receiving worse healthcare following the COVID-19 pandemic and 34.3% were concerned about access to quality care.
- The public overwhelmingly supported creating more public information about this problem, with 82.4% interested in having more focus on promoting patient safety.
“We believe the public should be informed and feel confident in the care they are receiving, and these findings underscore that there is still improvement to be made,” said David B. Mayer, MD, CEO of the Patient Safety Movement Foundation. “Our movement requires a collective effort to achieve patient safety across the globe and while we have made significant progress focused on educating the public about patient safety in the last year, we are committed to continuing to bring awareness to this important issue.”
The survey was conducted by ClearPath Strategies in March 2021. It consisted of 1,725 English-speaking individuals spanning six countries: Australia, India, Philippines, South Africa, United Kingdom and the United States. The “2021 Patient Safety Awareness Poll Results Compared to 2020 Assessment” white paper can be accessed here . An infographic summarizing the key findings can be accessed here .
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals, with more than three million deaths globally, as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero preventable patient harm and death. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005248/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
